Sign in
CompletedNo phase

A Study of the Sleepnet Elara APAP Device

Key facts

Who runs it
Sleepnet Corporation
Where
Auburn and St Louis, United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
89 people enrolled
Started
21 Apr 2026
Ended
20 Oct 2026
Type of study
Interventional
Treatments tested
  • Sleepnet Elara Treatment
Record updated
3 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Body weight ≥ 30kg
  • Willing and able to consent, adhere to study requirements and receive mask treatment
  • ≥ 18 years of age
  • Diagnosed with OSA (Total AHI >15 events/hr) by a practicing physician within the last 6 months. A re-diagnosis may be necessary to establish current baseline AHI in case there has been significant weight change or other co-morbidities since the previous diagnosis (per PI discretion)
  • Currently utilizing an APAP Device for ongoing treatment of OSA

Who cannot take part

  • Female currently bearing a child or intending to become pregnant prior to the sleep study
  • Acute otitis media inflammation (must be resolved prior to sleep study)
  • Has history of Cerebrospinal fluid leakage, craniocerebral trauma, intracranial trauma or pneumocephalus
  • Upper gastrointestinal bleeding that has not been effectively controlled
  • Severe coronary heart disease with left heart failure
  • Have another significant sleep disorder(s) that in the opinion of the investigator would confound the results of the study (e.g. periodic leg movements >15/hr or insomnia that would interfere with completing the sleep study)
  • Body weight < 30kg
  • Have implanted pacemaker, ICD or any other medical device that would interfere with the PSG results or safety of the subject undergoing the study
  • Has pneumothorax, pneumomediastinum
  • Ongoing shock from various causes untreated
  • Current epistaxis
  • Non-compliant with APAP usage (< 4 hours per night on 70% of nights)
  • Has obstructive vocal cord polyps
  • Excessive respiratory secretions and cough weakness
  • Weak spontaneous breathing
  • Tracheal intubation (nasal or oral) and tracheotomy
  • Severe nasal congestion from various causes
  • Lung bullae
  • Central sleep apnea index >5 events/hr

Where in United States

  • University Sleep Disorders CenterAuburn, United States
  • Clayton Sleep InstituteSt Louis, United States

About the trial

What the trial wants to find out

The goal of this study is to evaluate the effectiveness of the Elara APAP device.

The group in the trial

  • TreatmentTreatment being tested

    Sleepnet Elara Treatment

    Treatment: Sleepnet Elara Treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Open-label Study to Assess the Efficacy of the Elara APAP Device When Used in Patients With Obstructive Sleep Apnea
Record updated
3 November 2026